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Summary 
In this study, the structure of a novel 1.9-kb transcript coding for complement component 3 
(C3) is described.  This alternate  C3 is identical to the 3' end of the C3 message beginning at 
position 3300 of the C3 cDNA. Its transcription appears to be driven by an alternate promoter 
located within intron 8 of the C3 gene. This alternate C3 message contains an open reading 
frame that may encode a 536-amino acid-long protein identical to the 3' part of the C3 o~ chain. 
The resulting protein contains the complement receptor CR2 binding site. The suggested 5' 
end of coding region of the alternate C3 includes information for a potential hydrophobic leader 
peptide that would allow secretion  of the protein. In vitro assays with macrophage-depleted 
mouse splenic B cells indicate that an activity is secreted from cell lines transfected  with the 
alternate C3 cDNA. Together with Sepharose-bound immunoglobulin M-specific monoclonal 
antibodies and interleukin 2, it costimulates the proliferation of B cells. Implications for possible 
in vivo functions are discussed. 
T 
he  third  component of complement (C3) 1 and  the 
receptors that bind its activated fragments have been rec- 
ognized as  regulators  of humoral immune responses.  In 
humans, guinea pigs, and dogs, genetic deficiencies in specific 
components of the classical pathway (C1-C4) are associated 
with diminished primary antibody responses to T-dependent 
and -independent antigens (1-3) and low levels of certain Ig 
isotypes (4).  Treatment of mice with cobra  venom factor, 
which leads to C3 depletion by activating the alternative com- 
plement pathway, results in suppression of the antibody re- 
sponse to T-dependent (5) and -independent antigens (6). 
Furthermore, these mice fail to localize immune complexes 
on follicular  dendritic cells in germinal centers  and, thus, 
generate an impaired memory response to T-dependent an- 
tigens (7,  8). 
Our own previous experiments have provided further evi- 
dence for the role of C3 in B cell proliferation and its action 
through the CR2 receptor.  Proliferation of purified LPS- 
activated splenic B lymphocytes was found to be controlled 
by three restriction points in the cell cycle (9). The first, oc- 
curring immediately after mitosis, could be overcome by in- 
1 Abbreviations used in this paper: otp, c~-promoter; CAT, chloramphenicol 
acetyl transferase; C3, third component of complement; NF-IL-6, nuclear 
factor IL-6; ORF, open reading frame; RACE, rapid amplification ofcDNA 
ends. 
teractions of Sepharose-bound IgM-specific antibodies with 
surface IgM. The second restriction point, observed in the 
G1 phase, appeared to be influenced by factors contained in 
macrophage cell line-conditioned media. These factors were 
termed a-factors. The third restriction point, occurring in 
the G2 phase of the cell cycle, was found to be controlled 
by  factors  secreted  by  helper  T  cells. Experiments  have 
identified the latter activities  as IL-2 or IL-5 (10). In addi- 
tion, it was determined that macrophage-derived or-factor 
could be replaced by the human C3 fragments C3b and C3d 
(11). It is interesting to note that the C3 fragments had to 
be presented to B cells in polymerized or Sepharose-bound 
form to be costimulatory. Soluble fragments were found to 
be inhibitory for B cell proliferation. This activity was ap- 
parently mediated via the CR2 (CD21, C3d/EBV-receptor) 
since a peptide covering the CR2 binding site of C3 specifically 
inhibited the stimulation (10, 12). It has been proposed that 
a proteolytic cleavage product of the C3 protein, iC3i, might 
regulate B cell proliferation (13). 
Further evidence of the biological role for C3, its frag- 
ments, and CK2, comes from various  approaches.  In vivo 
studies involving mAbs directed against murine CK2 have 
resulted in a suppression of the primary antibody response 
(14-16). A soluble chimeric protein formed with the ligand 
binding site of CK2 and murine IgG1 has been shown to 
suppress a primary in vivo antibody response in mice (17). 
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shown to  synergize with  T  cell-derived factors,  inducing 
human B cell proliferation (18). Anti-CR2 antibodies or mul- 
tivalent C3d augment human B lymphocyte activation in the 
presence of PMA (19). Cross-linking of CK2 increases cyto- 
plasmic  Ca  2+  influx  induced  by anti-IgM  stimulation  of 
human B cells  (20-22).  Interaction  between ligand-loaded 
CK2 and cross-linked surface Ig was demonstrated by cocap- 
ping on murine B lymphocytes (23, 24). Furthermore,  CK2 
is a component of a signal transduction complex containing 
CD19 and several other components, and this complex is dis- 
tinct from the membrane IgM complex (22). B cell activa- 
tion by the IgM complex can be synergistically enhanced by 
the CK2-CD19  complex (22). 
It has generally been accepted that the ligand for CR2 is 
generated by proteolytic processing of C3. On the other hand, 
preliminary experiments from our laboratory have detected 
a 1.9-kb RNA that crosshybridized with C3 gene probes (25). 
Furthermore,  cell lines such as the plasmacytoma X63 and 
the T  cell hybridoma A32-26,  which produce and  secrete 
or-factor  activities, were found to express the 1.9-kb RNA. 
In contrast, cell lines that do not produce o~-factor activities, 
such  as  the  B  cell lines,  J558  and  Sp2/0,  the  T  cell line 
BW5147, and the fibroblast line Ltk-,  did not express the 
1.9-kb KNA. These preliminary experiments indicated that 
a correlation might exist between o~-factor production and 
the  expression  of a  1.9-kb  RNA hybridizing  to  C3  gene 
probes. 
In the present report, the structure of this novel, 1.9-kb, 
C3-related transcript is described. Cell lines, which by them- 
selves did not produce ol-factor activities,  were transfected 
with cDNA corresponding to the 1.9-kb KNA. The prod- 
ucts made and secreted by these transfectants indicated that 
c~-factor activity can be expressed from the  1.9-kb KNA. 
Materials  and Methods 
Tissue Culture Conditions.  The murine T cell hybridoma A32-26 
(26),  clones C4,  BS,  and  B6,  and  the  murine  plasmacytomas 
X63/Ag8-653 (27) and J558 (28), were cultured in Iscove's  modified 
Dulbecco's modified Eagles medium supplemented with 5% FCS, 
antibiotics, and 5  x  10 -5 M 2-ME. The L cell fibroblasts were 
cultured under the same conditions as above except that the 2-ME 
was omitted. 
RNA  Preparations and  cDNA  Libraries. Total RNA  and 
poly(A) + KNA were prepared according to previous reports (29). 
cDNA libraries were made as before (29) and cloned with EcoKI 
linkers in Xgt11 (Stratagene, La Jolla,  CA). 
Rapid Amplification of eDNA  Ends.  For  location  of oligo- 
nucleotides used, see Fig. 1. A specific primer within the known 
sequence (No. 1005, position 40004220 or No. CR2, position 3754- 
3785) (30) was used to make the first strand cDNA on poly(A) + 
mKNA; this was then tailed with poly(A). The second strand was 
primed with oligo dT linked to an adaptor for restriction enzyme 
sites. PCK amplification was performed between the adapter primer 
and a second C3-specific primer (No. 974, position 3940-3960 or 
No. 315 in case of CR2-primed first strand cDNA) (30) within 
the known sequence to increase the specifidty of the desired product. 
DNA Constructs.  All DNA constructs were made using con- 
ventional DNA techniques (29). PCK reactions were performed 
according to the manufacturer's specifications (Perkin Elmer Cetus, 
Norwalk,  CT). Intron  8 was PCR amplified using 28 nucleotide 
primers (starting position 3226 and 3326, respectively)  (30) in exons 
8 and 9, including restriction sites, and thereafter cloned into the 
pBluescript SK + vector (Stratagene) and named pSK~intr8.  The 
insert was sequenced according to the manufacturer's specifications 
(Sequenase, Cleveland, OH). The ,,~400-bp fragment o~p promoter 
used in the transfection vector was made by digesting the phsmid 
pSKofintr8 with BamHI and EcoRI (in the polylinker). The frag- 
ment was filled in by Klenow and then  ligated into the unique 
5' HindlII site (Klenow fall in) of the pUC-CAT and pUC-CAT-E, 
vectors (31). 
Transfection and Chloramphenicol  Acetyl Transfen~se  Assay.  Cells 
were transiently transfected using DEAE-dextran as described else- 
where (31) e~ept that 2.5  x  106 cells per transfection sample was 
used. Cell extracts were prepared 40-46 h after transfection and 
tested in chloramphenicol acetyl transferase (CAT) assay as described 
elsewhere (31). The TLC plates were measured using a phosphor 
imager (Compaq;  Molecular Dynamics, Inc., Sunnyvale, CA). 
Expression Vectors.  The open reading frame (OR.F) (starting at 
position  +143 [see Fig. 2], i.e., position 3443 to the 3' end of the 
normal C3 cDNA; 30) of the alternate C3 was amplified by PCK 
and cloned into the PSCT/TC vector (PSCT/TC-OKF)  for in vitro 
transcription/translation.  The insert was in vitro transcribed using 
T7 RNA polymerase followed by in vitro translation (reticulocyte 
lysates) in  the  presence of [3SS]methionine (Amersham  Corp., 
Arlington  Heights,  IL) according to the manufacturer's specifica- 
tions (Promega, Madison, WI). The in vitro translated products 
were analysed by SDS-PAGE gels. They were also used for im- 
munoprecipitations with two different goat anti-C3 antisera. The 
immunoprecipitated  products  were analysed by SDS-PAGE gels. 
The  ORF  was  also cloned  into  the  BCMGS-Neo  vector 
(BCMGS-Neo-ORF) which has a CMV promoter/enhancer  ele- 
ment, rabbit/~-globin splice rite, polyadenyhtion signal, SV40 origin 
of replication,  and the gene encoding neomycin resistance. This 
vector was introduced by electroporation into J558 plasmacytoma 
cells and Ltk- cells. After selection in G418-containing medium, 
resistant transfectants were analysed  by dot blot hybridizations for 
the presence of RNA corresponding to the insert (alternate C3). 
Positive cells were then transferred to serum-free media without 
G418 and 2-4 d later, supernatants  were collected and analyzed 
in the proliferation assay (see below). Over 95% of the transfected 
cells remained viable after the 2-4-d incubation  period. 
The B Cell Assa  7 System.  The B cell test system for co-factor 
activity, originally described as macrophage conditioned medium, 
was performed as described elsewhere (9, 32). Briefly, small resting 
B cells were prepared from C57BL/6 nu/nu spleens depleted of re- 
sidual T cells by anti-Thyl.2 and complement. The cells were sepa- 
rated according to their size by velocity sedimentation for 5 h and 
the fraction of small resting B cells was collected. These cells were 
depleted of macrophages by anti-Mac1 binding followed by mag- 
netic cell sorting (MACS) according to the manufacturer's specifica- 
tions (Miltenyi Biotec, Cologne, Germany). Purified B cells were 
cultured at 1.5  x  105 cells/ml in serum-free medium in the pres- 
ence of Sepharose-bound,  anti-IgM-specific  mAbs  and purified 
recombinant  II:2 (concentrations  according  to figure  legends). 
Serum-free supernatants  of the BCMGS-Neo-ORF transfected 
clones to be tested were added at 25%, unless indicated otherwise. 
l~eaults 
Clonin  e and Seq~ine of  the 1,9-kb  RNA S~cies Hymning 
with the C3 Gene.  Previous experiments from our labora- 
2080  Structure  of an Alternate Form of Complement C3 tory have detected a 1.9-kb RNA that crosshybridizes with 
C3 gene probes (30). A correlation between ol-factor produc- 
tion and the expression of this 1.9-kb RNA was found (25, 
and Cahen-Kramer, Y., unpublished observations). We there- 
fore set out to clone and characterize this 1.9-kb RNA spe- 
cies. Several cDNA  libraries  were  constructed  from  the 
ol-producing  A32-26 T cell line. cDNA clones hybridizing 
to the C3 cDNA probe were analyzed.  Fig.  1 B shows the 
sequenced parts of seven individual  cDNA clones, as indi- 
cated by the arrows.  All clones obtained showed sequence 
identity with the 3' end of the full-length  C3 cDNA. Since 
none of the sequences appeared to contain the fuU-length of 
the  1.9-kb  RNA,  the rapid  amplification  of cDNA ends 
(RACE [33]) was used to clone and sequence the 5' terminal 
part of 10 additional  cDNA (Fig. 1 C). The 5' end was fur- 
ther determined by primer extension analyses showing a re- 
sult  similar  to the RACE clones (Fig.  1 C). These results 
suggest that the short C3 message is not generated by alter- 
native splicing, since no additional  sequences were found in 
the cDNA clones that could have been spliced into the 5' 
end of the 1.9-kb message from another part of the gene. 
PCR experiments were performed on A32-26 cDNA using 
two oligonucleotides derived from the first C3 exon in con- 
junction with an oligonucleotide located within exon 9 of 
the cloned cDNA. No specific PCR amplification  products 
were found here when either of the two oligonucleotides from 
the first C3 exon was used (data not shown). This made it 
more improbable that the alternate  C3 message was gener- 
ated by alternative  splicing.  In summary,  a total of 1.8 kb 
cDNA was cloned and sequenced. All sequences were found 
to be identical with those of normal C3. With an expected 
additional  100-200 bp poly(A) tail,  this would correspond 
well to the length of a 1.8-1.9-kb mRNA. Furthermore, the 
experiments  described above make it likely that the 1.9-kb 
C3 mRNA initiates within the C3 gene around position 3300 
of the full-length  C3 cDNA (30) and therefore  represents 
a continuous 5' truncated version of the normal C3 mKNA. 
Genomic Sequences Upstream of the Transc@tion Start Site 
of the Alternate 1.9-kb mRNA.  The 1.9-kb alternate C3 RNA 
starts at position 3300 in the normal C3 cDNA. Informa- 
tion about intron/exonjunctions is not available  for the mouse 
C3 gene but has been determined for the human C3 gene 
(34). Comparison of human and mouse C3 cDNA sequences 
reveals a conserved basic organization of this gene. By analogy 
to human C3 intron/exon junctions, the 5' end of the alter- 
native  1.9-kb transcript  seems to be located  11 nucleotides 
into exon 9. There was no evidence for the 1.9-kb C3 mRNA 
being derived from alternative splicing of the normal C3 gene, 
and  the initiation  site appeared  to be very close to an in- 
tron/exon boundary. We therefore  attempted to clone  the 
5' sequences  including intron 8 to look for possible c/s-elements 
regulating transcription  of the 1.9-kb alternate C3 mRNA. 
The whole intron 8 has a length of 274 bp and the sequence 
revealed a putative TATA  box (35) at position  -26 and a CAAT 
box (36) at position  -51 relative to the presumed start site 
(Fig. 2). Other regulatory sequence motifs were also found. 
Particularly  striking  among them are an Spl consensus se- 
quence in opposite orientation at position -20 (37, 38) and 
a nuclear factor IL-6 (NF-IL-6) recognition site at position 
-139 (39). 
Promoter Activity Conferred by Intron 8 of the C3 Gene.  To 
test if the sequences 5' of the ORF in exon 9 could act as 
a promoter,  the 400-bp ot promoter sequence (c~p) was cloned 
upstream of the reporter gene, CAT, in the absence (crp-CA?) 
or presence (c~p-CAT-E) of the IgH chain,  Eu,  intron  en- 
hancer (Fig. 3 A). The constructs were transiently transfected 
into X63 plasmacytoma  cells shown to produce the 1.9-kb 
C3 transcript.  As seen in Fig. 3, B and C, the otp-CAT vector 
showed no activity. However, in the presence of the E/~ en- 
hancer, i.e., otp-CAT-Eu, the CAT activity was increased 10- 
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Figare  1.  (A) Structure of the 3' 
end of the cDNA encoding the C3 
o< chain and obtained cDNA clones 
from  the  alternate  1.9-kb  C3 
mRNA. The scale is in base pairs. 
(T) Trypsin;  (I) Factor I cleavage 
sites. (CR2-B) CR2 receptor bind- 
ing  site in the corresponding C3 
protein. The C3 cDNA probes (Pst 
I  fragments)  were  derived  from 
pML C3/4 (59). (315, CR2, 974, 
and 1005) Oligonucleotides used for 
PCR. amplification by the 5' RACE 
method. (B) cDNA clones obtained 
from the A32-26 cDNA libraries; 
(am~vs) sequenced parts. (C) Alter- 
nate C3 cDNA clones obtained by 
the 5' RACE method; transcription 
start site as determined by primer 
extension. Sequence  upstream of the translational  start codon for the alternate  C3 
-348 
GCTGGCTTCA  AACAGCCCAG  CTCTGCCTAT  GCTGCCTTCA  ACAACCGGCC CCCCAGCACC 
exon 8  m, 
-2m 
TGGGTAGCGG  GTTGTCAGCT CTGTCCCCTC  TGCCTCAACA TCCACGTGAG CAAAGCCTGA 
Intron 8  m 
-228 
TTCCCCACCA  GTGGTGGTCT  GGCCTCTCTC TGTCAAGGCT GCAGGGACTG AATGAGCCTT 
-188 
AGAGTCCI"rT  AAGCACCAGC I"T'rATGCGGC  TTr~A  AAAATCCATA  ACTGAGGGCT 
NFdL8 
-1(~ 
CTGCACCAGG  CCCTCTCTGG  TCAI"rGGTGG  GTGAAGATGT  CAATCTATCT  ACTAAAAC~A 
CAAT 
-48  +1 
ATCGAGTCTC  AGCTGGTGTT  CCT&TA&CTC CGCCCC  AGCT  GACAGCCTAC GTGGTCAAGG 
TATA  Spl  exon 9  lira 
§ 
TCTTCTCTCT  AGCTGCCAAC CTCATCGCCA TCGACTCTCA CGTCCTGTGT  GGGGCTGTrA 
+73 
AATGGTTGAT 
+133 
TCTGGAGAAA  CAGAAGCCGG  ATGGTGTCTT TCAGGAGGAT  GGGCCCGTGA 
TTCACCAAGA  A~ 
Mot 
Figure  2.  Sequence of Y end of exon 8, intron 8 (274 bp) and 5' end 
of exon 9 of mouse C3 ot chain. Oligonucleotides derived from the mouse 
C3 cDNA which correspond to intron/exon  boundaries in the human 
gene, were used to PCR amplify mouse C3 intron 8 from genomic DNA 
(see Materials and Methods). The transcription start site determined by 
primer extension is set to + 1. Intron 8 starts at position - 285. The exon 
8/intron 8/exon 9 boundaries are shown. The ORF starts at position +143. 
Underlined are TATA  element, CAAT  box, Spl site, and a potential NF-II:6 
site. These sequence  data are available  from EMBL/GenBank/DDBJ  under 
accession number Z37998. 
fold  whereas  a  control  construct  (CAT-E,)  showed  only 
background activities. These data suggest that the sequences 
5' of the OKF in exon 9 of the C3 gene can serve as a promoter. 
In Vitro Translation of the Alternative C3 cDNA.  The lon- 
gest ORF in the 1.9-kb transcript potentially encodes a 536- 
amino  acid protein  initiating  with  an in-frame,  relative to 
C3, AUG. This AUG is located 143 nucleotides downstream 
from the putative 5' end of the transcript (Fig. 2). For cloning 
into expression vectors, the OKF of the 1.9-kb transcript was 
amplified by PCR from the A32-26 cDNA. The PCK product 
was cloned in  the PSCT/TC  vector for in vitro  translation 
and in the BCMGS-Neo  vector for stable expression in eu- 
caryotic cells. Fig. 4 A  shows the result of an in vitro transla- 
tion experiment  in which  the products were analyzed on a 
polyacrylamide gel.  Lane 1 correspond to the control trans- 
lation product. Lanes 2-4 correspond to three different clones 
containing  the OKF cDNA after 15 min of in vitro transla- 
tion (30 and 60 min showed similar results, data not shown). 
The size of the putative alternate C3 protein could be 55-60 
kD (arrow Fig.  4 A).  The in vitro  translated  proteins  were 
also tested in immunoprecipitations for the expression of an- 
tigenic  determinants  of C3  using  different  anti-mouse  C3 
polyclonal  antibodies  (Fig.  4  B).  Purified  goat  anti-mouse 
C3c  (Fig.  4  B,  lane  1)  and  a  goat  anti-C3  antiserum  (Fig. 
4 B, lane 2)  were both able to precipitate an in vitro trans- 
lated alternative C3 protein with a molecular mass of 55-60 
kD,  whereas  normal goat  serum (Fig.  4 B, lane 3)  did not 
precipitate any protein. This shows that a 55-60-kD protein 
can be made in vitro from the vector containing the alternate 
Figure  3.  (A) A 400-bp fragment containing the potential o~ promoter 
sequence (see Fig. 2; position  -348 to  + 54) including the potential cap 
site, TATA  box, CAAT box, and the NF-Ib6 site was cloned upstream 
of the reporter gene CAT, either in the absence (otp-CAT)  or presence (otp- 
CAT.E~,) of the IgH intron enhancer (E,).  CAT-E, correspond to vector 
without promoter. The CAT structural gene contains its own translation 
start codon. (/3) The constructs in A were transiently  transfected  into X63/0 
myeloma cells shown to produce the 1.9-kb C3 transcript. After 2 d, the 
amount of CAT enzyme produced was measured in a CAT assay. One 
representative experiment (duplicate) is shown including actual percent 
CAT activity. (C) Three independent experiments as in B with different 
plasmid preparations. 
C3  cDNA  and  this  protein  can  be  recognized  by  anti- 
C3-specific  antibodies. 
B Lymphocyte Costimulatory  Activity Secreted  by Transformants 
Expressing the Alternate C3  mRNA.  The  BCMGS  Neo 
plasmid, carrying the OKF of the alternate C3 cDNA,  was 
introduced  into  the J558  mouse  plasmacytoma  and  Ltk- 
2082  Structure of an Alternate Form of Complement  C3 Figure 4.  (A)  PAGE gel after 
15 min in vitro translation of:  a 
positive control (lane I) and three 
individual samples (lanes  2-4) con- 
raining the alternate C3 cDNA in 
the PSCT/TC vector. (B) Immuno- 
precipitation of the in vitro trans- 
lated products in A with: purified 
goat anti-mouse  C3c (lane I), goat 
anti-mouse C3 serum (lane 2) and 
normal goat serum  (lane  3). (Anvws, 
A and B) Position of the potential 
alternate C3 protein. 
fibroblast cell lines.  Both  are  negative for endogenous  C3 
RNA. G418-resistant  transformants were tested by RNA dot 
blot analysis for the presence of the transfected message using 
a C3 cDNA probe (data not  shown).  The supernatants  of 
11 positive J558 and 10 positive Ltk-  transformants,  as de- 
termined by the dot blot assay, were chosen to be tested for 
ol-factor activity. Figure 5:I shows the result of such an ex- 
periment. When the resting B cells were cultured in medium 
alone (Fig.  5 A) in the presence of anti-Ig  antibodies (Fig. 
5 B) or in the presence of anti-Ig antibodies, IL-2 and condi- 
tioned medium from nontransfected L cells (Fig.  5 C), they 
did not proliferate. In fact, initially as a source of rlL-2,  su- 
pernatants from L cells transfected with BMCGS/Neo/IL-2 
were used and in the absence of c~-factor, scored negative in 
the above assay. However, if the B cells were cultured in the 
presence of anti-Ig antibodies, IL-2 and conditioned medium 
from L cells transfected with the alternative C3 cDNA, they 
did proliferate  (Fig. 5 D), E~eriments with supernatants from 
J558 transformants showedfimilar results (data not shown). 
In another set of experiments, different concentrations of 
L cell-conditioned medium (as source of oe-factor) and of rlL-2 
were tested. The titration curve in Fig. 6 (left) suggests that 
at 25% of L cell-conditioned medium, maximum prolifera- 
tion appears to be reached.  Experiments  with  supernatants 
from J558  transformants  showed  similar  results  (data  not 
shown). In case of rlL-2 (Fig.  6, middle) a plateau is reached 
at  100 U/ml.  When  the increase  in the number of B220 + 
cells in the culture was monitored with time (Fig.  6 Hght), 
the cells were found to divide continuously for 6 d.  There- 
after,  the cells began to die, i.e.,  the cell numbers decreased 
(data not shown).  At this stage,  they could not be rescued 
even in fresh medium containing all stimulatory factors, similar 
to earlier studies with anti-IgM- or LPS-stimulated splenic 
2083  Cahen-Kramer  et al. 
B cell cultures. Thus, L cells and J558 cells transfected with 
a cDNA coding for the longest ORF in the alternate 1.9-kb 
C3 transcript produce and secrete c~-factor activity. The ac- 
tivity is costimulatory with IL-2 and anti-Ig  and is able to 
promote B cell proliferation for at least five to six divisions 
in vitro. 
Discussion 
In this paper we have elucidated the structure of a variant 
1.9-kb transcript of the mouse C3 gene initiated from an in- 
ternal  promoter.  It encodes a 60-kD protein  that  acts as a 
costimulator in the proliferation of mature B lymphocytes, 
together with IgM-specific antibodies and rlL-2.  These findings 
raise  a series  of intriguing  questions.  Is  the alternate  tran- 
script produced by normal cells and which cells make it? Is 
its production regulated by external stimuli such as IL-6 and 
how is this transcription regulated on the level of the internal 
promoter? How is this transcription  made constitutive in many 
cell lines? Does the three-dimensional  structure of the alter- 
nate C3 protein differ from normal  C3 and its proteolytic 
degradation  products?  Can it be secreted? Which develop- 
mental  stage(s) of B  cell development  is (are)  the target(s) 
of this protein?  What  is the physiological role of alternate 
C3 in vivo? 
In previous preliminary experiments, a variant 1.9-kb tran- 
script of the C3 gene has been detected in the cell lines of 
mouse and human T and B lymphocytes, monocytes, macro- 
phages,  and fibroblasts.  However, it  appeared to be absent 
in normal resting and activated mouse B lymphocytes (25, 
and Lernhardt,  W., personal communication).  These obser- 
vations are in line with the data shown in this paper where 
normal B cels do not proliferate in the presence of IgM-specific Figure 5.  Proliferation of mac- 
rophage and T cell-depleted splenic 
B cells after 5 d in culture:  (A) in 
serum-free medium alone; (/3)  in the 
presence of Sepharose-bound anti- 
IgM antibodies; (C) in the presence 
of Sepharose-bound anti-IgM anti- 
bodies, 500 U  rib2, and 10% me- 
dium conditioned for 2 d with non- 
transfected L cells; and (D) in the 
presence of Sepharose-bound anti- 
IgM antibodies, 500 U  rlL-2, and 
10% medium conditioned for 2 d 
with L cells transfected with the al- 
ternate C3 cDNA. 
antibodies and rlL-2 alone. Since small numbers of normal 
macrophages can provide c~-factor  activity in B cell prolifera- 
tion assays (32), they might in fact transcribe a 1.9-kb alter- 
nate transcript and translate and secrete the alternate C3 pro- 
tein from it. Detection of the alternate C3 transcript  has so 
far been hampered by our inability to purify suffacient  quan- 
tities of normal macrophages producing c~-factor  activity to 
allow a Northern blot analysis. Such  analysis  cannot be replaced 
by ILNA PCR analysis since it would not be able to distin- 
guish a normal 5.6-kb C3 transcript from the alternate 1.9-kb 
form. The detection of the protein product of the alternate 
C3 transcript  would best be done with specific mAbs able 
to distinguish  this protein from normal C3 and its proteo- 
lytic degradation  products (iC3, C3b,  and C3d), but such 
mAbs are not yet known. 
An alternate 1.9-kb C3 transcript could, in principle, arise 
either from alternative splicing, alternative initiation of tran- 
scription,  or from a second, truncated C3 gene in the ge- 
nome. We have  been unable to detect any nucleotide sequences 
at the 5' end of the 1.9-kb mRNA that are not contiguous 
with the published sequence of the 3' half of the C3 gene. 
This makes it unlikely that a region further upstream,  e.g., 
from the 5' promoter region of the C3 gene, would be spliced 
into the 1.9-kb mRNA. Whereas our results show that the 
1.9-kb transcript can be derived from an alternative internal 
transcription  start site, we have also searched for the possible 
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Figure 6.  Proliferation of macrophage and 
T cell-depleted splenic B cells. Different cul- 
ture conditions were analyzed and the number 
of  cells/ml  determined.  (Left)  Titration of 
serum-free superuatants of o~-factor-produdng 
L  cells in the  presence of anti-Ig with  or 
without 500 U 1I.-2. Open symbols are super- 
natants  of nontransfected  cells with (1-1) or 
without (A) Ib2; closed symbols are superna- 
tants of cells transfected with the alternate C3 
cDNA with (D) or without (&) Ib2. Assayed 
after 5 d in culture. (M/ddk) Titration of IL-2 
in the presence  of ami-lg with (@) and without 
(O) 25% c~-superuatant. Assayed after 5 d in 
culture. (Right) Growth kinetics (Days) of in 
vitro proliferating B cells. Open symbols are 
cell numbers/ml  in the presence of antiqg and 
nontransfected cell supernatants  with ([]) or without 500 U  Ib2 (A), Closed symbols are cell numbers in the presence of anti-lg and transfected 
cell superuatants  with (D) or without 500 U  IL-2 (A). 
2084  Structure  of an Alternate  Form of Complement C3 existence of a second, truncated C3 gene. The mouse C3 gene 
has been mapped to chromosome 17, outside the MHC class 
III gene cluster (40) and has been estimated to be ~24 kb 
in size (41).  No C3-related or pseudo genes have been seen 
in these studies. We searched for C3 pseudo genes that could 
encode the truncated C3 mRNA in Southern blots of genomic 
DNA from A32-26 cells and from the inbred mouse strains 
from which the cell line was generated. All the DNA prepa- 
rations, digested with several restriction enzymes, showed 
a hybridization pattern compatible with the existence of a 
single copy gene (data not shown). This also makes it un- 
likely that the transformed A32-26 cell line, from which the 
alternate C3 transcript was sequenced, carries a chromosome 
aberration at the site of the C3 gene. 
An analogous 1.9-kb C3 transcript has been found in the 
human B cell line Raji (Lernhardt, W., personal communi- 
cation). By comparison of C3 protein sequences of different 
species it becomes evident that the AUG codon found at the 
beginning of the long ORF of the alternative C3 transcript 
is conserved among all available sequences, i.e., mouse (30), 
human (42), pig (43), and rabbit (44). This suggests the pos- 
sibility that the alternate C3 product could be a B cell-co- 
stimulatory factor in all these species. 
The fact that intron 8 was active in the transcription assay 
suggests that it can act as a promoter. Without an enhancer, 
it has low promoter activity. This is similar to the normal 
C3 promoter which shows low activity in itself, an activity 
that can be upregulated with IL-1 plus IL-6 (45). Inspection 
of the intron sequences 5' of the putative transcription start 
site of the alternate C3 reveals several sequences with homol- 
ogies to known c/s-acting elements of other promoters. At 
position  -26 to  -20 (Fig. 2) a TATA box is found (35) and 
at position -  51 to -47 there is a CAAT box known to bind 
the CTF/NF-1 transcription factor (36). Downstream of the 
TATA box is a GC-rich sequence CCGCCCC, which matches 
the consensus motif for the Spl transcription factor binding 
site (GGGGCGG) on the opposite strand (37).  A NF-IL-6 
recognition site is found at nudeotide - 139 to - 130. NF-IL-6 
has been reported to be a member of the C/EBP family of 
lencine zipper proteins (39). Its binding site has not only been 
found in the promoter of the IL-6 gene but in several other 
cytokine and various acute-phase protein genes (39). NF-IL-6 
mRNA is induced by LPS, IL-6, and IL-1, along with TNF 
and glucocorticoids, all well-known mediators of an acute 
phase response (46-48). It is therefore conceivable that in an 
acute phase reaction, an activation by LPS or IL-6 could directly 
induce expression of the short C3 gene product. It remains 
to be investigated whether the NF-IL-6 motif binds the cor- 
responding NF in cells that can regulate the transcription 
of the alternate C3. This cannot be done with the cell lines 
expressing the alternate C3 that we have tested so far, since 
they are not responsive to LPS or IL-6 (data not shown). 
Normal macrophages might be a more likely source of cells 
for an investigation as to whether IL-6 or an inducer of IL-6 
expression have direct or indirect effects on the alternative 
C3 expression. 
We have not yet undertaken a detailed study of the mode 
by which the alternate C3 protein may be released from the 
2085  Cahen-Kramer et al. 
cells. It is unlikely that death of the transfected cells would 
be the mechanism by which B cell costimulatory activity con- 
ditions the supernatant medium used in our proliferation assays. 
Furthermore, the structure of the alternate C3 protein offers 
the possibility for its active secretion. A hydropathy plot (49) 
of the deduced amino acid sequence of the alternate, trun- 
cated C3  predicts a  hydrophobic region at  the NH2  ter- 
minus. This hydrophobic region is found between residues 
13 and 23 and may represent a signal sequence active in secre- 
tion of the protein from the cells (50,  51). 
The alternate C3 protein lacks the thiolester group that 
is involved in rapid covalent binding of the activated C3 mol- 
ecule (C3b) to cell surfaces, complex carbohydrates, or im- 
mune complexes. However, it includes the CR2 binding site 
(12). Due to its shorter length, it has a free cysteine residue 
which, in the normal C3 molecule, is involved in a disul- 
phide bridge. This raises the possibility that the alternative 
C3 product may be different in three-dimensional structure 
and may, under certain conditions, even form a homodimer 
or a heterodimer. Previous experiments with C3d have indi- 
cated that CR2 had to be cross-linked to costimulate prolifer- 
ation of B cells. Monovalent ligands, by contrast, were shown 
to suppress  B lymphocyte activation and proliferation (11, 
19, 24, 52). If the alternate C3 protein can form dimers, then 
CR2 could either be cross-linked with itself or with another 
receptor. Other experiments (22) have suggested that associ- 
ation of CR2 with CD19 is needed for B cell proliferation, 
suggesting that such heterocross-linking could be as effec- 
tive as homocross-linking (of CR2) in B cell stimulation. 
The apparent strong hydrophobicity of the alternate C3 pro- 
tein has so far prevented the characterization of mAbs that 
might specifically recognize it, as well as binding experiments 
that could determine whether it really interacts with CR2. 
Our assay system has previously defined three restriction 
points in the cell cycle of primary murine B lymphocytes. 
The three synergistically acting ligands are anti-Ig specific 
antibodies acting early in G1 of the cell cycle, macrophage- 
derived oe-factors, or C3d in insoluble form controlling the 
entry to S phase, and IL-2 or IL-5 as T helper-derived/3-factors 
in G2 phase. All other recombinant interleukins "so far tested 
(IL-1, -3, -4, and -6), at concentrations as high as 1-10 #g/ml, 
were not able to replace any of these factors (10). We show 
here that the alternate C3 protein appears  to act in place of 
o~-factor or insolubilized C3d in the cell cycle. The strong 
hybrophobicity of the alternate C3 protein has so far prevented 
absorption experiments with polyclonal C3-specific antibodies 
to test whether the growth-promoting activity for B lym- 
phocytes is indeed conveyed by this protein. Therefore, it re- 
mains a rather unlikely possibility that the alternate C3 in- 
duces, in fibroblasts and other transfected cells, the production 
of a (yet unknown) B cell stimulatory factor. 
We would like to propose a model for a possible in vivo 
activity of the alternative C3 which acts either in the early 
phase of an immune response or as an additional cofactor, 
released by macrophages in an acute phase response, to trigger 
B cell proliferation. The model uses the following two ob- 
servations as its basis:  (a) The alternate C3 might be pro- 
duced in vivo by monocytes and macrophages (11, 32);  (b) The transcription of the truncated message might be regu- 
lated by NF-IL-6 which is involved in the regulation of genes 
in acute phase and inflammation. The interaction between 
macrophages and primary B cells may occur in the microen- 
vironment of a localized  immune response,  i.e.,  at the site 
of inflammation caused by tissue injury, bacterial or viral in- 
fection, parasites, or neoplasia. C3 expression, including that 
of the alternate C3, might be upregulated by these external 
influences. Upregulation could also occur within lymphoid 
organs at the sites of first encounter with the antigen pre- 
sumed to be in splenic red pulp or in the paracortical T-zone 
of lymph nodes (53). 
There is other evidence for a role of C3 (and possibly of 
the alternate C3 protein) in primary B cell responses,  espe- 
cially in those mediated by LPS. LPS or lipid A stimulation 
of either peripheral blood monocytes or the human mono- 
cyte line U937 increases C3 synthesis 5-30-fold (54, 55). Fi- 
broblasts are induced to synthesize C3 and Factor B with 
15- and 40-fold increases, respectively, by IL-6 and IL-1, and 
it is suggested that LPS could act, at least in part, through 
induction of IL-6 and possibly IL-1 (47,  48).  The changes 
in synthesis are achieved through elevated mKNA levels (47, 
55, 56). As these results are significantly different from the 
50% increase in serum C3 concentration during the acute 
phase (57),  it was suggested that tissue-specific regulation 
of local C3 concentration plays a very important role in the 
local inflammatory  response. Possibly the C3 product derived 
from the alternative C3 mRNA accounts for some of these 
effects and could lead to the activation of primary B cells. 
It has been proposed previously that complement is in- 
volved in long-term maintenance and generation of B cell 
memory by mediating uptake of antigen by follicular den- 
dritic cells that also express CR2 (58). Our model shifts the 
primary role of C3, in the form of the alternate C3, to an 
earlier part of the B cell response. However, the two models 
are not mutually exclusive if alternate C3 acts early and full- 
length C3 acts later in the response. 
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